Bot Chart, page-10880

I have changed my forward thinking about the potential benefit of seeing Sofdra sales results in the USA three months after launch. Not 6. This will
coincide nicely with Christmas 2024 as I believe BOT will be very impressed with the uptake. Sure I am prophesying but if the demand for
take up aligns with their initial studies, it may be a blockbuster type of scenario. Management know that they have to hit the ground running so in
the next 7 months, any publicity is good publicity. Short term price movements mean nothing when FDA approval hits.

The only thing I can think off out of left field is post the human trail for english comprehension which I hope they finish before January 25th, then
the FDA may review this in under the 6 month time frame. Just think of the absolute stupidity of leaving an urgently requested trial which will be approved sitting on a table for 6 months. It defies logic doesn't it that patients cannot have access to this earlier. Sure it's not killing anyone unlike the mrna
quick to market but the frickin dope association fda may just sit on this one. Or they may not. I don't care but that's about the only outta left field
narrative for me.